IBJNews

Study: Arthritis drug co-developed by Lilly shows promise

Back to TopCommentsE-mailPrintBookmark and Share

Incyte Corp. says a study of an experimental pill developed with Eli Lilly and Co. for rheumatoid arthritis showed the drug reduces inflammation in patients’ joints at all doses.

At the highest dose of 10 milligrams, 72 percent of patients taking the drug daily had a 20-percent reduction in joint swelling after 24 weeks, 44 percent had a 50-percent drop and 28 percent had a 70-percent decline, Wilmington, Del.-based Incyte said in a prepared statement. By comparison, 32 percent of patients taking placebos had a 20-percent drop in inflammation, 13 percent had a 50-percent decline and 3 percent had a 70-percent drop, the company said.

The drug, previously known as INCB28050, will be called LY3009104, and Indianapolis-based Lilly will be responsible for future clinical trials, Incyte said in its statement. Headache, upper respiratory tract infections, and diarrhea were the most frequently reported side effects mentioned by the 125 patients who took part in the study, the company said.

Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases. If the drug makes it to market, Lilly could pay another $665 million to Incyte for reaching various milestones along the way.

The latest study results suggest that “the compound has the potential to become a welcome addition” to current therapies, said Maria Greenwald, a Palm Desert, Calif., rheumatologist who led the study. The findings were released Thursday at the American College of Rheumatology meeting in Atlanta.

In rheumatoid arthritis, the body’s immune system attacks itself, causing joint inflammation and swelling that can lead to progressive destruction of the joints. The disease affects about 1 percent of the world’s population.

The pill is one of a family of experimental treatments for rheumatoid arthritis targeting a protein called JAK that leads to joint destruction. Pfizer Inc. also reported results showing an experimental JAK-targeted medicine that reduced pain and inflammation in a trial released at the rheumatology meeting.

Three biotechnology companies are developing JAK drugs: Incyte, Rigel Pharmaceuticals Inc. of San Francisco, Calif., and Cambridge, Mass.-based Vertex Pharmaceuticals Inc.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. This is still my favorite Mexican restaurant in town. What I do love about the new version is it is much quieter than the most recent version. TV's were off, the music wasn't too loud, and the wait staff were not hyperactive like they had been the past few times I had been there. I just wish they would bring back the MOLE for the enchiladas!

  2. Not a bad paper. There is a need for local community news and city government issues. Don't really need the owner's constant national political rants. We all know where they stand by now.

  3. What nice people. Menard should've known better than to team up with the guy who robbed and drove Conseco to ashes. I'm surprised Timothy Durham isn't involved in this.

  4. Hello, I am Maris Peters, currently living in Texas city, USA. I am a widow at the moment with three kids and i was stuck in a financial situation in August 2014 and i needed to refinance and pay my bills. I tried seeking loans from various loan Companies both private and corporate but never with success, and most banks declined my credit. But as God would have it, I was introduced to a Man of God a private loan lender who gave me a loan of $65,000USD and today am a business owner and my kids are doing well at the moment, if you must contact any firm or company with reference to securing a loan without collateral , no credit check, no co signer with just 2% interest rate and better repayment plans and schedule, please contact Mr William David. He doesn’t know that am doing this but am so happy now and i decided to let people know more about him and also i want God to bless him more.You can contact him through his email: Davidloanfirm@yahoo.com

  5. It is beyond me how anyone can think this was a "bad deal" for the state! If they could take the money back then, yes, but they can't! Protections were built in the agreement. Now, if they roll the roads up and take them away, I will agree that it was a bad deal. Otherwise, the only way to have paid for the infrastructure that was badly needed was for the state to issue bonds....that is a four letter synonym for debt folks!!

ADVERTISEMENT